Literature DB >> 10699346

Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.

N G Lee1, S B Jung, B Y Ahn, Y H Kim, J J Kim, D K Kim, I S Kim, S M Yoon, S W Nam, H S Kim, W J Park.   

Abstract

The aim of this study was to determine whether the antibodies raised in burn patients by active immunization with a Pseudomonas aeruginosa OMPs vaccine have a protective efficacy against infection with P. aeruginosa. The binding patterns with P. aeruginosa OMPs of immunized burn patient sera were similar to the sera of immunized healthy humans as determined by immunoblot and immunoprecipitation analyses. The sera pooled from immunized burn patients after three immunizations showed a significantly higher opsonophagocytic-killing activity than the corresponding pre-immune sera, while the sera from unimmunized patients collected at the same day did not. Passive immunization of mice with post-immune sera of burn patients significantly enhanced the survival rate upon a lethal challenge with P. aeruginosa compared to the pre-immune sera, indicating the protective ability of the antibodies induced in burn patients by immunization. These results suggest that anti-P. aeruginosa OMPs antibodies elicited in burn patients by active immunization are protective against infection with P. aeruginosa, and provide a rational for further development of the vaccine for prevention against P. aeruginosa infection in burn patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699346     DOI: 10.1016/s0264-410x(99)00479-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

Review 1.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

2.  Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa.

Authors:  B M Price; D R Galloway; N R Baker; L B Gilleland; J Staczek; H E Gilleland
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

3.  Opr86 is essential for viability and is a potential candidate for a protective antigen against biofilm formation by Pseudomonas aeruginosa.

Authors:  Yosuke Tashiro; Nobuhiko Nomura; Ryoma Nakao; Hidenobu Senpuku; Reiko Kariyama; Hiromi Kumon; Saori Kosono; Haruo Watanabe; Toshiaki Nakajima; Hiroo Uchiyama
Journal:  J Bacteriol       Date:  2008-04-04       Impact factor: 3.490

Review 4.  Understanding Pseudomonas aeruginosa-Host Interactions: The Ongoing Quest for an Efficacious Vaccine.

Authors:  Maite Sainz-Mejías; Irene Jurado-Martín; Siobhán McClean
Journal:  Cells       Date:  2020-12-05       Impact factor: 6.600

5.  Protection against Pseudomonas aeruginosa lung infection in mice by recombinant OprF-pulsed dendritic cell immunization.

Authors:  Lucia Peluso; Cristiana de Luca; Silvia Bozza; Antonio Leonardi; Gloria Giovannini; Alfonso Lavorgna; Gaetano De Rosa; Massimo Mascolo; Loredana Ortega De Luna; Maria Rosaria Catania; Luigina Romani; Fabio Rossano
Journal:  BMC Microbiol       Date:  2010-01-13       Impact factor: 3.605

6.  Pseudomonas aeruginosa mannose-sensitive hemagglutinin inhibits proliferation and invasion via the PTEN/AKT pathway in HeLa cells.

Authors:  Tie-Qiu Yin; Xuan Ou-Yang; Fang-Yan Jiao; Lu-Ping Huang; Xu-Dong Tang; Bi-Qiong Ren
Journal:  Oncotarget       Date:  2016-06-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.